Company / EPS (Diluted)
Taysha Gene Therapies, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.36
FY2025
5-year range
-$4.64 / -$0.36
FY2021-FY2025
Trend
+62.5%
vs FY2024
Sector context
#62 of 204
Health Care
What the data says
At $-0.36, Taysha Gene Therapies, Inc.'s eps (diluted) ranks #62 of 204 in the Health Care sector. EPS (Diluted) has increased for 3 consecutive years, from $-4.64 in FY2022 to $-0.36 in FY2025.
Based on SEC 10-K filings.
-0.36 in FY2025.
Improved from $-3.78 to $-0.36 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#62 of 204 in Health CareTop 30% of 204This company -$0.36 Sector average -$0.89
▼
+59.4% above sector average
Key checks
Key Insights
- Taysha Gene Therapies, Inc.'s eps (diluted) has grown for 3 consecutive years.
- In FY2025, eps (diluted) increased 62.5% year-over-year.
- Ranks #62 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.36 | +62.5% |
| FY2024 | -$0.96 | +74.6% |
| FY2023 | -$3.78 | +18.5% |
| FY2022 | -$4.64 | +0.0% |
| FY2021 | -$4.64 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026